Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from GSK

Why world's first malaria shot won't reach millions of children who need it

After decades of work, the World Health Organization endorsed the first-ever malaria vaccine last year - a historic milestone that promised to drive back a disease that kills a child every minute.

Reuters

The Daily Biotech Pulse: GSK To Supply 50M Flu Vaccine Doses To US, FDA Lifts Hold On Greenwich's Cancer Immunotherapy Trial, Connect Biopharma Sees CBP-201 Topline Data Sooner

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

This is how Nigerians are fighting an epidemic with highest number of child pneumonia deaths in the world

Nigerian photographer Yagazie Emezi travels across her home country to document the ongoing epidemic of child pneumonia

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

India’s patent law safeguards under fire

The new recommendation reduces the period within which patent applications can be challenged to six months

The Hindu

Ideaya Nominates Potential First-In-Class Pol Theta Helicase Inhibitor In Collaboration With GSK

Ideaya Biosciences Inc (NASDAQ:IDYA) has selected a potential first-in-class Pol Theta Helicase development candidate, a small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK plc (NYSE:GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase candidate in combination with niraparib, GSK's PARP inhibitor, in tumors with…

Benzinga

IBD Screen Of The Day: Global Leaders Highlight These Top Health Care Stocks

GSK announced positive results in a late-stage study on a new Covid-19 vaccine targeted to combat the omicron variant.

Investors Business Daily

GSK Shares Encouraging Data From Chronic Hepatitis B Candidate

GSK plc (NYSE:GSK) announced promising interim results from the B-Clear phase 2b trial of bepirovirsen in people with chronic hepatitis B (CHB). The data showed that bepirovirsen reduced hepatitis B surface antigen (HBsAg) levels and hepatitis B virus (HBV) DNA after 24 weeks of treatment. In the group of 227 patients on standard…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Finally An Omicron-Blocking Shot? Sanofi, GSK Say Yes

Sanofi stock bounded higher Friday after its GSK-partnered Covid shot tamped down on omicron infections in a Phase 3 study.

Investors Business Daily

Sanofi-GSK's Beta-Containing COVID-19 Vaccine Shows Efficacy Against Omicron

Sanofi SA (NASDAQ:SNY) and GSK plc (NYSE:GSK) have announced positive data from their vaccine trial of adjuvanted bivalent D614 and Beta (B.1.351) vaccine candidate. "Sanofi-GSK's vaccine is the first candidate to demonstrate efficacy in a placebo-controlled trial in an environment of high Omicron variant circulation," Sanofi said in a statement. The bivalent vaccine targets the…

Benzinga

Kynos Therapeutics appoints chief finance officer

She will combine her current role as COO at NodThera while supporting the Edinburgh medtech firm

Insider UK

Pharmaceutical giant GSK opens new £90m North East manufacturing site

The company says the opening of Q Block will allow the Barnard Castle site to strengthen its global role

Birmingham Post

Analyzing GSK's Short Interest

GSK's (NYSE:GSK) short percent of float has fallen 17.24% since its last report. The company recently reported that it has 6.02 million shares sold short, which is 0.24% of all regular shares that are available for trading.

Benzinga

Antibiotic Makers Adopt Their Own Environmental Safeguard Standards

The AMR Industry Alliance, a life-sciences coalition set up to provide sustainable solutions to curb antimicrobial resistance (AMR), is adopting its standards limiting toxic emissions. The Alliance published its Antibiotic Manufacturing Standard: Minimizing the risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from manufacturing human antibiotics. The…

Benzinga

Morning Brief: Top Financial Stories Dominating on Friday, June 10

Reuters Rebranded McDonald’s Restaurants To Reopen In Russia

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

GSK Shows Positive Pivotal Phase III Data For Its RSV Vaccine Candidate

GSK plc (NYSE:GSK) intends to engage with regulators immediately after reporting positive headline results from a pre-specified efficacy interim analysis of the AReSVi 006 phase III trial, it anticipates regulatory submissions in the second half of 2022. AReSVi 006 is a phase III trial investigating GSK’s respiratory syncytial virus (RSV) vaccine candidate…

Salon

Why the malaria vaccine took 35 years

Malaria's complex biology played a role in the delay, but experts say there was also a lack of urgency and funding

Benzinga

GSK Confirms Consumer Healthcare Unit Spin-off: What Investors Should Know

Close on the heels of an M&A deal, GlaxoSmithKline plc (NYSE: GSK) confirmed the spin-off of the consumer healthcare business it jointly owns with U.S. pharma giant Pfizer, Inc.

Benzinga

Morning Brief: Top Financial Stories Dominating on Wednesday, June 1

Reuters Redbird Capital Buys Italian Football Club AC Milan

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Pfizer To Quit GSK's Consumer Health JV Following Its Spin-Off

Pfizer Inc. (NYSE:PFE) intends to sell its 32% investment in Haleon, a consumer health joint venture with GSK plc (NYSE:GSK), after the business is spun out as an independent listed company in July, reported Reuters. Pfizer had previously indicated that it might seek to sell its stake in Haleon, a consumer health company and…

Benzinga

Unilever Jumps After Nelson Peltz Joins Board

Unilever plc (NYSE: UL) shares traded higher by 8% on Tuesday after the company announced activist investor Nelson Peltz is joining the company's board of directors.

Investors Business Daily

GlaxoSmithKline Announces $3.3 Billion Buyout To Square Off With Pfizer, Merck

GlaxoSmithKline announced Tuesday a $3.3 billion deal to buy pneumonia vaccine-maker Affinivax. But GSK stock dipped at the close.

The Independent UK

GSK strikes deal to buy US vaccine firm Affinivax

It comes as the UK pharmaceutical business seeks to bolster its vaccine operation as part of a shake-up of its portfolio.

The Hindu

GSK looking to invest more in Hyderabad

KTR holds discussions with Global R&D Head of GSK Consumer Health in London

StockNews.com

3 Healthcare Stocks That Pay Dominant Dividends

Despite heightened market volatility, the healthcare industry is expected to grow significantly in 2022 amid surging chronic diseases worldwide, an aging population, increasing healthcare expenditure, and numerous medical advancements. So, we think it could be wise to invest in fundamentally sound healthcare stocks Gilead (GILD), Takeda (TAK), and GlaxoSmithKline (GSK).…

Benzinga

ARWR: Phase 3 PALISADE Study of ARO-APOC3 Underway…

By David Bautz, PhD NASDAQ:ARWR READ THE FULL ARWR RESEARCH REPORT

1 … 10 11 12 13

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations